Pharmacologic inhibition of HNF4α prevents parenteral nutrition associated cholestasis in mice

[1]  F. Suchy,et al.  Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition–associated cholestasis in mice , 2021, Hepatology.

[2]  M. Lovell,et al.  NF‐κB Regulation of LRH‐1 and ABCG5/8 Potentiates Phytosterol Role in the Pathogenesis of Parenteral Nutrition–Associated Cholestasis , 2021, Hepatology.

[3]  A. Mobasheri,et al.  The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicity. , 2021, Toxicology letters.

[4]  D. Burrin,et al.  Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates , 2021, Nutrients.

[5]  Hongbo Hu,et al.  Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study , 2020, Signal Transduction and Targeted Therapy.

[6]  R. Sokol,et al.  Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management , 2020, Hepatology International.

[7]  R. Sokol,et al.  New Insights Into Intestinal Failure–Associated Liver Disease in Children , 2020, Hepatology.

[8]  A. Jain,et al.  Mechanisms of Parenteral Nutrition-Associated Liver and Gut Injury. , 2019, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[9]  M. Yeh,et al.  Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases , 2019, World journal of gastroenterology.

[10]  J. Marquardt,et al.  Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer—from Tumor Development to Therapeutic Implications , 2019, Cancers.

[11]  F. Suchy,et al.  Macrophage-derived IL-1β/NF-κB signaling mediates parenteral nutrition-associated cholestasis , 2018, Nature Communications.

[12]  A. Humar,et al.  Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis , 2017, PloS one.

[13]  Robert H. Squires,et al.  The extent of intestinal failure-associated liver disease in patients referred for intestinal rehabilitation is associated with increased mortality: an analysis of the Pediatric Intestinal Failure Consortium database. , 2017, Journal of pediatric surgery.

[14]  M. Pakarinen,et al.  Parenteral Plant Sterols Accumulate in the Liver Reflecting Their Increased Serum Levels and Portal Inflammation in Children With Intestinal Failure , 2017, JPEN. Journal of parenteral and enteral nutrition.

[15]  Shao-Cong Sun,et al.  NF-κB signaling in inflammation , 2017, Signal Transduction and Targeted Therapy.

[16]  W. Cai,et al.  Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure , 2016, Scientific Reports.

[17]  Jiping Zeng,et al.  Mutual amplification of HNF4α and IL-1R1 composes an inflammatory circuit in Helicobacter pylori associated gastric carcinogenesis , 2016, Oncotarget.

[18]  D. Kelly,et al.  Total Parenteral Nutrition-Induced Cholestasis: Prevention and Management. , 2016, Clinics in liver disease.

[19]  C. Hill,et al.  Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. , 2014, Journal of hepatology.

[20]  N. Pace,et al.  Specific Microbiome Changes in a Mouse Model of Parenteral Nutrition Associated Liver Injury and Intestinal Inflammation , 2014, PloS one.

[21]  P. Heikkilä,et al.  Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure. , 2014, The American journal of clinical nutrition.

[22]  K. Setchell,et al.  Phytosterols Promote Liver Injury and Kupffer Cell Activation in Parenteral Nutrition–Associated Liver Disease , 2013, Science Translational Medicine.

[23]  M. Lovell,et al.  Toll‐like receptor 4–dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury , 2012, Hepatology.

[24]  C. Williamson,et al.  Nuclear receptor-driven alterations in bile acid and lipid metabolic pathways during gestation. , 2011, Biochimica et biophysica acta.

[25]  T. Luedde,et al.  NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[26]  M. Grompe,et al.  Therapeutic liver reconstitution with murine cells isolated long after death. , 2010, Gastroenterology.

[27]  Daniel L. Koller,et al.  Differentially expressed genes strongly correlated with femur strength in rats. , 2009, Genomics.

[28]  R. N. Saha,et al.  MAPK p38 Regulates Transcriptional Activity of NF-κB in Primary Human Astrocytes via Acetylation of p651 , 2007, The Journal of Immunology.

[29]  David A. Brenner,et al.  Mechanisms of Liver Injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways , 2006 .

[30]  H. Aburatani,et al.  Dysregulated expression of P1 and P2 promoter‐driven hepatocyte nuclear factor‐4α in the pathogenesis of human cancer , 2006, The Journal of pathology.

[31]  M. Makishima,et al.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. , 2001, Gastroenterology.

[32]  M. Boehnke,et al.  The role of HNF4A variants in the risk of type 2 diabetes , 2005, Current diabetes reports.